For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer’s DiseaseEriksdotter-Jönhagen M.a, d · Linderoth B.b, e · Lind G.b, e · Aladellie L.f · Almkvist O.a, i · Andreasen N.a, d · Blennow K.j · Bogdanovic N.a · Jelic V.a, d · Kadir A.a · Nordberg A.a, d · Sundström E.a, h · Wahlund L.-O.a, d · Wall A.k · Wiberg M.c, g · Winblad B.a, d · Seiger Å.a, d, h · Almqvist P.b, e, l · Wahlberg L.a, l
Departments of aNeurobiology, Caring Sciences and Society, bClinical Neuroscience and cClinical Science, Karolinska Institutet, Departments of dGeriatrics, eNeurosurgery, fEmergency Medicine and gRadiology, Karolinska University Hospital, hStockholms sjukhem, and iDepartment of Psychology, Stockholm University, Stockholm, jDepartment of Clinical Neuroscience, Clinical Neurochemistry Laboratory, University of Göteborg, Göteborg, and kDepartment of Radiology, Oncology and Radiation Sciences, Uppsala University, Uppsala, Sweden; lNsGene A/S, Ballerup, Denmark
Background/Aims: Degeneration of cholinergic neurons in the basal forebrain correlates with cognitive decline in patients with Alzheimer’s disease (AD). Targeted delivery of exogenous nerve growth factor (NGF) has emerged as a potential AD therapy due to its regenerative effects on the basal forebrain cholinergic neurons in AD animal models. Here we report the results of a first-in-man study of encapsulated cell (EC) biodelivery of NGF to the basal forebrain of AD patients with the primary objective to explore safety and tolerability. Methods: This was an open-label, 12-month study in 6 AD patients. Patients were implanted stereotactically with EC-NGF biodelivery devices targeting the basal forebrain. Patients were monitored with respect to safety, tolerability, disease progression and implant functionality. Results: All patients were implanted successfully with bilateral single or double implants without complications or signs of toxicity. No adverse events were related to NGF or the device. All patients completed the study, including removal of implants at 12 months. Positive findings in cognition, EEG and nicotinic receptor binding in 2 of 6 patients were detected. Conclusions: This study demonstrates that surgical implantation and removal of EC-NGF biodelivery to the basal forebrain in AD patients is safe, well tolerated and feasible.
© 2012 S. Karger AG, Basel